文献速递中医妇科中药与中成药合理使用中医内科

中药治疗围绝经期非结构性异常子宫出血:系统评价与Meta分析

Chinese herbal medicines for the treatment of non-structural abnormal uterine bleeding in perimenopause: A systematic review and a meta-analysis.
PubMed 文献 · Complement Ther Med · 2018-09-26

结果显示中药在月经正常化率、改善更年期症状、血红蛋白计数方面有优势,且不良反应和复发率更低;但止血率与西药无显著差异。因临床异质性高、方法学质量低且缺乏安慰剂对照,结论有限。

要点

  • 中药较西药提高月经正常化率(RR 1.20,95%CI 1.06-1.34,P=0.003)。
  • 中药改善更年期症状并提升血红蛋白,不良反应和复发率更低。
  • 止血率与西药无显著差异(RR 1.02,95%CI 0.95-1.10,P=0.62)。

核心结论

  • 与西药相比,中药可能为围绝经期非结构性异常子宫出血有效、可接受且安全的治疗。
  • 因临床异质性高、方法学质量低且无适当安慰剂对照,结论尚不确定且有限,需未来进一步验证和更新。

研究设计与样本

  • 系统评价与Meta分析,检索7个数据库自建库至2017年12月31日。
  • 纳入比较中药与西药治疗围绝经期非结构性异常子宫出血的随机对照试验(RCT)。
  • 采用Cochrane偏倚风险评估工具评价方法学质量,Review Manager 5.3软件进行数据分析,结果以风险比(RR)或均数差(MD)及95%置信区间(CI)表示。

主要发现

  • 与西药相比,中药在月经正常化率方面有优势(RR 1.20;95%CI 1.06-1.34;P=0.003)。
  • 中药改善更年期症状:RR 1.20(95%CI 1.10-1.31,P<0.0001);MD -2.80(95%CI -3.35至-2.25,P<0.00001)。
  • 中药提升血红蛋白计数:MD 7.85(95%CI 4.05-11.65,P<0.0001)。
  • 中药不良反应发生率更低(RR 0.23,95%CI 0.12-0.43,P<0.00001),复发率更低(RR 0.38,95%CI 0.26-0.54,P<0.00001)。
  • 止血率方面,未发现中药与西药疗效存在差异的充分证据(RR 1.02,95%CI 0.95-1.10,P=0.62)。

临床怎么用

  • 围绝经期非结构性异常子宫出血可考虑中药作为改善月经正常化、更年期症状及血红蛋白的选项。
  • 中药可能降低不良反应和复发风险,但止血效果与西药相当,需结合患者具体情况选择。
  • 应用时需注意证据质量有限,临床决策应个体化并关注后续研究更新。

局限性

  • 纳入研究临床异质性高。
  • 方法学质量低。
  • 缺乏适当的安慰剂对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chinese herbal medicines (CHM) have been the mainstream therapy in Asia for thousands of years and become more popular as the alternative treatment recently. The objective of this study is to evaluate the efficacy and safety of CHM for non-structural abnormal uterine bleeding (AUB) in perimenopause. METHODS: Seven databases were searched from inception to December 31 st, 2017. Randomized controlled trials (RCTs) which compared CHM versus western therapy in treating non-structural AUB in perimenopause were extracted. The primary outcome measures were hemostasis rate, normalization rate of menstruation, hemoglobin count, and improvement of menopausal symptoms. The secondary outcome measures were adverse effects and recurrence rate. The methodological quality of included trials was assessed in line with the criteria of the Cochrane Risk of Bias assessment tool. Data analyses were performed by Review Manager 5.3 software. The results were expressed as risk ratio (RR) or mean difference (MD) with a 95% confidence interval (CI). RESULTS: Fifteen RCTs with 1344 participants were analyzed. Compared with Western therapies, CHM showed advantages in normalization rate of menstruation (RR 1.20; 95% CI 1.06-1.34;P = 0.003), improving menopausal symptoms (RR 1.20, 95% CI 1.10-1.31, P <0.0001; MD -2.80, 95% CI -3.35 to -2.25, P <0.00001) and the hemoglobin count (MD 7.85, 95% CI 4.05-11.65, P <0.0001) with lower incidence of adverse reactions (RR 0.23, 95% CI 0.12 to 0.43, P <0.00001) and lower recurrence rate (RR 0.38, 95% CI 0.26 to 0.54, P <0.00001). However, we found insufficient evidence that CHM was any more or less effective than CWT for hemostasis rate (RR 1.02, 95% CI 0.95-1.10, P = 0.62). CONCLUSIONS: The findings of our study suggest that CHM may be the effective, acceptable and safe treatment for non-structural abnormal uterine bleeding during perimenopause when compared with Western medicine. However, due to high clinical heterogeneity, low methodological quality and without a proper placebo control, the conclusion is inconclusive and limited, and it should be further examined and updated in future work.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Shang Y, Lu S, Chen Y, et al. Chinese herbal medicines for the treatment of non-structural abnormal uterine bleeding in perimenopause: A systematic review and a meta-analysis. Complement Ther Med. 2018. PMID: 30477849. doi:10.1016/j.ctim.2018.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。